ACHV

MKT CAP:$214M

Achieve Life Sciences, Inc.

Market Cap

$214M

Healthcare·Biotechnology·🇨🇦 Canada·NASDAQ

Healthcare·Biotechnology·🇨🇦·NASDAQ

Stock Price

$4.15-$0.82 (-16.50%)

Apr 23, 2026

Company Details

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisin...

CEO

Richard A. Stewart

IPO Date

Oct 12, 1995

Website

www.achievelifesciences.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$55M

EPS (Diluted)

-$1.30

Free Cash Flow

-$49M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

FY 2025

Mar 24, 2026

$0EPS -$1.25

Q4 2025

Mar 24, 2026

$0EPS -$0.28

Q3 2025

Nov 6, 2025

$0EPS -$0.28

Q2 2025

Aug 7, 2025

$0EPS -$0.37

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$7M
Q2 22	$0	$0	-$10M
Q3 22	$0	$0	-$13M
Q4 22	$0	$0	-$11M
Q1 23	$0	$0	-$9M
Q2 23	$0	$0	-$8M
Q3 23	$0	-$100.0K	-$7M
Q4 23	$0	$0	-$4M
Q1 24	$0	$0	-$6M
Q2 24	$0	$0	-$8M
Q3 24	$0	$0	-$12M
Q4 24	$0	$0	-$12M
Q1 25	$0	$0	-$13M
Q2 25	$0	$0	-$13M
Q3 25	$0	-$54.0K	-$15M
Q4 25	$0	-$57.0K	-$15M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$7M	-$7M
Q2 22	-$8M	-$8M
Q3 22	-$11M	-$11M
Q4 22	-$11M	-$11M
Q1 23	-$8M	-$8M
Q2 23	-$7M	-$7M
Q3 23	-$5M	-$5M
Q4 23	-$4M	-$4M
Q1 24	-$5M	-$5M
Q2 24	-$5M	-$5M
Q3 24	-$10M	-$10M
Q4 24	-$9M	-$9M
Q1 25	-$11M	-$11M
Q2 25	-$9M	-$9M
Q3 25	-$11M	-$11M
Q4 25	-$18M	-$18M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$0
Q3 22	$0
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$15.0K
Q4 23	$6.0K
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$3.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	-9.5%
Q2 22	—	-10.9%
Q3 22	—	+88.8%
Q4 22	—	+52.7%
Q1 23	—	+18.7%
Q2 23	—	-23.4%
Q3 23	—	-48.0%
Q4 23	—	-59.6%
Q1 24	—	-30.3%
Q2 24	—	+9.3%
Q3 24	—	+89.7%
Q4 24	—	+177.9%
Q1 25	—	+115.5%
Q2 25	—	+49.0%
Q3 25	—	+17.9%
Q4 25	—	+20.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$823.0K	—
Q2 22	$840.0K	—
Q3 22	$829.0K	—
Q4 22	$778.0K	—
Q1 23	$1M	—
Q2 23	$1M	—
Q3 23	$1M	—
Q4 23	-$10.0K	—
Q1 24	$1M	—
Q2 24	$1M	—
Q3 24	$1M	—
Q4 24	$1M	—
Q1 25	$2M	—
Q2 25	$3M	—
Q3 25	$2M	—
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$4M	$3M	—
Q2 22	$7M	$3M	—
Q3 22	$10M	$3M	—
Q4 22	$9M	$2M	—
Q1 23	$6M	$3M	—
Q2 23	$5M	$3M	—
Q3 23	$4M	—	$3M
Q4 23	$2M	$2M	—
Q1 24	$3M	$3M	—
Q2 24	$5M	$3M	—
Q3 24	$8M	$5M	—
Q4 24	$7M	$5M	—
Q1 25	$7M	$6M	—
Q2 25	$7M	$6M	—
Q3 25	$5M	$9M	—
Q4 25	$4M	—	$11M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$36M	$0	$36M
Q2 22	$29M	$0	$29M
Q3 22	$18M	$0	$18M
Q4 22	$25M	$0	$25M
Q1 23	$17M	$0	$17M
Q2 23	$25M	$0	$25M
Q3 23	$20M	$0	$20M
Q4 23	$16M	$0	$16M
Q1 24	$66M	$0	$66M
Q2 24	$15M	$47M	$61M
Q3 24	$10M	$33M	$43M
Q4 24	$13M	$22M	$34M
Q1 25	$13M	$10M	$23M
Q2 25	$52M	$4M	$55M
Q3 25	$32M	$16M	$48M
Q4 25	$21M	$15M	$36M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	9M	+0.1%	+54.3%
Q2 22	10M	+2.0%	+30.5%
Q3 22	10M	+0.5%	+2.6%
Q4 22	14M	+39.6%	+43.2%
Q1 23	18M	+32.4%	+89.4%
Q2 23	19M	+6.3%	+97.4%
Q3 23	21M	+10.9%	+117.9%
Q4 23	21M	+0.2%	+56.4%
Q1 24	25M	+18.3%	+39.8%
Q2 24	34M	+37.0%	+80.2%
Q3 24	34M	+0.1%	+62.6%
Q4 24	35M	+0.5%	+63.1%
Q1 25	35M	+0.5%	+38.5%
Q2 25	35M	0.0%	+1.1%
Q3 25	51M	+47.1%	+48.5%
Q4 25	53M	+4.4%	+54.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	16
Q2 22	$0	16
Q3 22	$0	16
Q4 22	$0	20
Q1 23	$0	20
Q2 23	$0	20
Q3 23	$0	20
Q4 23	$0	22
Q1 24	$0	22
Q2 24	$0	22
Q3 24	$0	22
Q4 24	$0	25
Q1 25	$0	25
Q2 25	$0	25
Q3 25	$0	25
Q4 25	$0	28

Revenue / Employee